Vijayakumar Karthik, Kiren George Koshy, Arsha Asok, Selvarajan Chettiar
Subacute sclerosing panencephalitis presenting as severe depression in an adult
BMJ case reports
group b streptococcus major cause neonatal disease natural history studies linked maternally transferred antigroup b streptococcus capsular polysaccharide antibodies protection infant group b streptococcus disease previous studies capsular polysaccharide antibody concentration european populations used maternal infant sera nonstandardised assay study aimed evaluate anticapsular polysaccharide igg concentrations associated protection invasive group b streptococcus disease finnish infants retrospective casecontrol study used cord sera finnish dipp study repository obtained jan 1 1995 dec 31 2017 included infants aged 6 months younger group b streptococcus infection cases healthy infants controls enrolled infants invasive neonatal group b streptococcus 55 cases matched controls 229 controls aged 6 months younger identification finnish health registers measured anticapsular polysaccharide igg serotypes iav concentration using standardised immunoassay estimated relationship disease risk using bayesian model used derived riskconcentration curve predict potential efficacy sixvalent group b streptococcus capsular polysaccharide vaccine gbs6 based previously reported immunogenicity data 32 58 55 cases group b streptococcus cases due serotype iii antiserotype iii streptococcus capsular igg concentrations higher serotype iiimatched controls cases p0001 01200266 gml serotype iiispecific igg estimated confer 7590 risk reduction serotype iii disease universal riskconcentration curve aggregating results across six serotypes yielded similar results application curve gbs6 immunogenicity data predicted maternal immunisation 80 efficacious prevention infant group b streptococcus disease higher neonatal anticapsular polysaccharide serum igg concentration birth correlated reduced risk infant group b streptococcus disease finland based results maternal group b streptococcus capsular conjugate vaccine currently development predicted efficacious pfizer